Alimta ® (pemetrexed for injection)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Alimta Summary of Product Characteristics (SmPC)

Alimta® (pemetrexed): Cisplatin Dose Sequencing

Cisplatin should be administered 30 minutes after pemetrexed.

UK_cFAQ_PEM092_CISPLATIN_SEQUENCING
UK_cFAQ_PEM092_CISPLATIN_SEQUENCING
en-GB

Dosing Sequence Rationale

Adequate Hydration

Patients should receive appropriate hydration prior to and/or after receiving cisplatin.1 The administration of cisplatin 30 minutes after pemetrexed is to allow for a saline flush, as well as any needed prehydration for cisplatin administration.1

Synergistic Effects

Pemetrexed is a pyrimidine and purine inhibitor and therefore it may influence cisplatin in the formation or the repair of formed adducts. Given that both chemotherapeutic agents are cell-cycle specific, their effect on the cell cycle can alter their individual cytotoxic effects.2,3

The interaction of pemetrexed and cisplatin may be dependent on the sequence of drug exposure, as well as on the tumor type. An in vitro study demonstrated that the simultaneous exposure to pemetrexed and cisplatin produced antagonistic effects in A549 lung, MCF7 breast and PA1 ovarian carcinoma cells, but additive effects in WiDr colon carcinoma cells.4

In contrast, the same study demonstrated that pemetrexed followed by cisplatin produced synergistic effects in MCF7 cells, greater than additive effects in A549 and PA1 cells, and additive effects in WiDr cells. Cisplatin followed by pemetrexed produced antagonistic effects in A549, MCF7, and PA1 cells and additive effects in WiDr cells. The investigators concluded that the administration of pemetrexed prior to cisplatin would be the preferred sequence.4

Pemetrexed was administered prior to cisplatin in both the pivotal trial for Malignant Pleural Mesothelioma (MPM) and the first-line treatment of Non Small Cell Lung Cancer (NSCLC).5,6 The same dosing sequence was maintained in recent trials for advanced NSCLC.7-9

Dosing, hydration and anti-emetic treatment

The recommended dose of pemetrexed is 500 mg/m2 of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle.10 

Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (see also cisplatin Summary of Product Characteristics for specific dosing advice).10

Indication

Pemetrexed in combination with cisplatin is indicated

  • for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology, and
  • for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.10

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Jäckel M, Köpf-Maier P. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother Pharmacol. 1991;27(6):464-471. http://dx.doi.org/10.1007/BF00685161

3Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol. 1997;39(6):521-531. http://dx.doi.org/10.1007/s002800050608

4Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res. 2006;16(2):85-95. https://doi.org/10.3727/000000006783981215

5Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136

6Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non–small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11(2):690-696. http://clincancerres.aacrjournals.org/cgi/content/abstract/11/2/690

7Tachihara M, Dokuni R, Okuno K, et al. Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer. Thorac Cancer. 2020;11(9):2536-2541. https://doi.org/10.1111/1759-7714.13567

8Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. J Clin Oncol. 2013;31(23):2895-2902. http://dx.doi.org/10.1200/JCO.2012.47.1102

9Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092. http://dx.doi.org/10.1056/NEJMoa1801005

10Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands

Date of Last Review: April 28, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request